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Abstract- To explore glycemic control, and adverse events of Iranian people with uncontrolled type 2 
diabetes after initiation of long-acting basal insulin, glargine. People with uncontrolled type 2 diabetes that 
was on at least two oral anti-diabetic drugs (OAD) were enrolled in this observational prospective study. 
Insulin glargine was prescribed by physicians in the course of routine clinical practice. Patients were followed 
for 24 weeks. Insulin doses were titrated to reach fasting blood sugar (FBS) target between 90 mg/dl and 130 
mg/dl. HbA1c and adverse events were recorded at baseline, week 12, and week 24. Form a total of 292 
participants, 243 patients completed the study. HbA1c, FBS, postprandial glucose, total cholesterol, 
triglycerides, and low-density lipoprotein cholesterol, but not body mass index decreased during the study. 
The proportion of poorly controlled patients (HbA1C>9%) decreased from 172 (58.9%) to 39(13.4%), and 
21(7.2%) during follow up. Controlled glycemia (HbA1C<7%) was detected in 7(2.4%), 48 (16.4%) and 56 
(19.2%) of patients at baseline, week 12 and week 24. Hypoglycemia was reported in 5.1% and 3.4% of the 
participants in the week at 12 and 24, respectively. Patients felt more satisfied with their blood glucose 
control, timing and choices of meals, and hypo/hyperglycemic experiences. Insulin glargine initiation in 
people with uncontrolled type 2 diabetes on 2 OADs is associated with significant improvement in metabolic 
control.  Insulin glargine has good safety profile and well tolerated by the patients. 
© 2018 Tehran University of Medical Sciences. All rights reserved.  
Acta Med Iran 2018;56(4):249-254. 
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Introduction 
 
The total prevalence of diabetes in the world will 
increase from 415 million in 2015 to 642 million in 
2040 (1). This increase is in part due to high prevalence 
of obesity which increased from 13.6% in 1999 to 
19.6% in 2005 and 22.3% in 2007 (2), sedentary life 
(40%; adult population 2007) (3), low fruit and 
vegetable consumption (4) and hypertension (26,6%; 
adult population 2007) (5) The estimated annual cost per 
diabetic patient was 2.7 times higher respectively than 
that of non-diabetic subjects. For the Iranian population, 
the direct and indirect costs of diabetes were estimated 
to be $537 m and $140 million, respectively in 2004-05, 
of which $356 m of direct costs and $80 million of 
indirect costs were estimated to be attributable to 
diabetes. Approximately 18% of Iranian diabetic 
subjects had at least one known microvascular or 
macrovascular complication (6). Several studies have 
shown that tight glycemic control could reduce these 
complications (7-10). Nevertheless, a high proportion of 
patients remain poorly controlled (11,12). Mirzazadeh et 
al., showed that about 57% of Iranian diabetic subjects 
had a fasting plasma glucose level equal or greater than 
130 mg/dL (13).  
Insulin therapy in type 2 diabetes is generally 
reserved for patients unresponsive to diet, exercise, and 
oral antidiabetic agents (OADs). After 5-10 years of 
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clinically recognized type 2 diabetes, a majority of 
patients will need insulin administration as a part of their 
therapeutic regimen to maintain target glycemic control 
(14,15). American Diabetes Association and European 
Association for the Study of Diabetes recommended the 
early addition of insulin therapy in patients who do not 
reach glycemic goals (16). Early insulin therapy is 
known to diminish the deleterious process of lipotoxicity 
directly or indirectly (17). Insulin exerts an inhibitory 
effect on oxidative stress caused by sustained 
hyperglycemia and glucose variability in non-insulin 
treated type 2 diabetes (18). Many patients and 
physicians, however, are reluctant to initiate insulin 
therapy for a variety of reasons, including concerns 
regarding the risks of hypoglycemia, needle phobia, a 
fear of weight gain and the perceived complexity of 
insulin regimens (19,20). Insulin glargine (LANTUS, 
Sanofi-Aventis, Paris, France), a long-acting basal 
insulin analog providing relatively peak-free insulin 
levels and a 24-h duration of action following once-daily 
administration, has facilitated several barriers and 
disadvantages associated with conventional insulin 
therapies to be overcome (21). In people with type 2 
diabetes, insulin glargine is associated with a lower risk 
of hypoglycemic events vs. NPH insulin (22-26), with at 
least equivalent glycemic control (27-30) and less 
weight gain. In this open-label observational study, we 
explored the efficacy and safety of early insulin therapy 
in type 2 diabetic subjects who were on OADs and 
failed to reach the recommended metabolic targets.  
  
Materials and Methods 
 
Eligible participants were people with type 2 
diabetes, with diabetes duration less than 5 years, on 2 
OADs, and with inadequate glycemic control (HbA1C 
>7%). Pregnant and breastfeeding mothers, patients 
younger than 18 years, subjects with severe dysglycemia 
(HbA1C >10%) or co-morbidities, hospitalized or 
severely ill patients and those previously treated with 
insulin in out-patient settings were excluded. Insulin 
glargine was prescribed by physicians in the course of 
routine clinical practice as single daily injection. 
Titration and dose adjustments were done by the 
physicians. The target glycemic control was defined as 
FBS <130 and >90 mg/dl. Changing the dose of OADs 
was at the discretion of the physicians. Hypoglycemic 
events in relation to daily activities and need to 
hospitalization were recorded.  Patients were weighted, 
and their HbA1c and lipid panel were determined at 
baseline, week 12 and week 24. This study was 
conducted in accordance with the principles of the 18th 
World Medical Assembly (Helsinki, 1964) and the 
applicable amendments. Ethics Committee of Iran 
University of Medical sciences reviewed and approved 
the study protocol. All patients gave written informed 
consent and received complementary Glucose meter and 
educational classes.  Data were analyzed and handled 
anonymously. Data quality control and verifications 
were performed with on-site audits and patient contacts 
based on standard protocol.  
 
Statistical analyses 
Main endpoints were percentage of patients with 
HbA1c<7% at week 12 and week 24, HbA1c changes 
from baseline, hypoglycemic events. Mean standard 
deviation and frequencies with 95% confidence interval 
are reported when appropriate. For the changes in 
HbA1C in addition to t-test and analysis of Variance, 
general regression model was used. Statistical analyses 
were conducted with SPSS Software version 19.  
 
Results 
 
Two hundred and ninety-two type 2 diabetic patients 
(175 females) were enrolled for this nation-wide multi-
center study. Twenty-two endocrinologists all over the 
country enrolled the study.  The study started November 
2009 and the last patient last visit was performed in May 
2011. Characteristics of the participants at baseline are 
summarized in table 1. Patients aged 51.8 ± 10.3 years 
and they were typically urban dwellers (91%) and obese 
(70%). Biguanides were the most common OAD used in 
255 patients (87.3%) followed by sulphonylureas in 227 
(77.7%). Thiazolidines were used in 38, alpha-
glucosidase inhibitors in 17, and glinides in 5 subjects. 
Biguanides were continued in 238 (81.5%) and 
sulphonylureas in 159 (54.5%) patients after initiation of 
insulin glargine. The effectiveness of basal insulin 
initiation on metabolic variables is presented in table 2. 
HbA1c, FBG and 2 hour PPG levels as well as total 
cholesterol, LDL, and triglycerides but not BMI and 
blood pressure decreased significantly during the study 
(P<0.001 for the trends). The mean decrease in HbA1c 
was 1.8% (±1.4). , and the mean decrease in FBG was 
92.3 ± 78.8 mg/dl. Reductions in 2-h PPBG levels were 
also observed over the 24-week observation period, the 
mean decrease in 2-h PPBG was 111.9 ± 106.2 mg/dl. 
The differences were significant from the baseline to the 
week 12 for the HbA1c, FBG and 2 hour PPG levels as 
well as total cholesterol and triglycerides. From week 12 
to week -24, the only significant variable which 
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deceased further was HbA1c (P=0.002 for Sidak test). 
At baseline, 172 (58.9%) of patients had HbA1c ≥9; this 
figure reduced to 39(13.4%) at week 12 and 21(7.2%) at 
week 24. Good glycemic control (HbA1C<7%) was 
detected in 7(2.4%), 48 (16.4%) and 56 (19.2%) of 
patients consequently at baseline, week 12 and week.  
 
Table 1. Baseline characteristics of the participants 
 n=292 
Age (years) 51.8 (±10.3) 
Duration of diabetes (months) 44.9 (±17.6) 
BMI(Kg/m2) 27.8 (±4.8) 
Gender (Female) 175 (60%) 
Obesity (BMI≥30) 205 (70%) 
  
  
  
  
  
Location 
Urban 267 (91%) 
Rural 25 (9%) 
Education status 
No formal education 45 (15%) 
Primary 111 (38%) 
Secondary 88 (30%) 
Higher  48 (17%) 
Micro-vascular complications 67 (30%) 
Macro-vascular complications 37(13%) 
Percentages (%) or standard deviations (SD) are presented in the parentheses 
 
 
Table 2. Baseline, week 12, and week 24 data for effectiveness of basal insulin initiation 
 Baseline Week 12 
Mean 
difference  
from 
baseline 
Week 24 
Mean 
difference  
from week 12 
Patients with 3-
valid readings 
P  
HbA1c (%) 9.2 (±1.4) 7.9 (±1.1) 1.42 7.5 (±1) 0.38 243 0.001 
BMI(kg/m2) 27.9 (±4.7) 27.8 (±4.4)  28.1 (±4.4)  238 NS 
FBS(mg/dl) 220.7 (±69.5) 139.4 (±35) 81.96 130.3 (±36.3) 10.02 241 0.001 
PPG(mg/dl) 295.4 (±92.7) 194.8 (±51.3) 108.48 182.9 (±46.6) 12.47 234 0.001 
Triglycerides(mg/dl) 199.6 (±108.4) 170.2 (±82.3) 35.52 162.6 (±60.1) 9.17 197 0.001 
Cholesterol(mg/dl) 187.9 (±48.1) 175.1 (±36.7) 18.1 167.9 (±31.1) 7 181 0.001 
LDL(mg/dl) 109.8 (±38.9) 97.9 (±30) 8.03 94.3 (±23.5) 8.84 162 0.001 
HDL(mg/dl) 44.7 (±11.2) 44.5 (±9.2)  44.3 (±9.2)  152 NS 
SBP(mmHg) 125.5 (±15.3) 124.3 (±13.4)  124 (±12.7)  225 NS 
DBP(mmHg) 79.1 (±10.8) 79.2 (±7.2)  79.6 (±6.9)  206 NS 
Data are mean and standard deviations in parentheses.  
Glycated hemoglobin, HbA1C; Body mass index , BMI; Fasting Blood Sugar, FBS; Post-prandial Glucose, PPG; High-Density Lipoprotein, HDL; Low-
Density Lipoprotein, LDL; Systolic Blood Pressure, SBP; Diastolic Blood Pressure, DBP 
General linear models for multiple measurements were designed 
NS indicates no significant difference 
 
 
The mean initial starting dose of insulin was 12.1 
(8.2) IU/day. This increased to 20.2 (9.1) U/day at week 
24 (Figure 1). The clinical hypoglycemia was reported 
in 15 cases (5.1%) during the first 12 weeks (9 subjects 
≤2 and others 3 to 5 events); and 10 cases (3.4%) 
between the week 12 and 24 (9 subjects≤ 2 and a patient 
4 events). The most frequently reported hypoglycemic 
symptom was tremor and weakness. The reported rate of 
all hypoglycemic episodes was less than 5%. No major 
and or nocturnal hypoglycemia was reported during the 
entire period of the study. 
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Figure 1. Mean Basal Insulin glargine dose (IU/day) at initiation, week 12 and week 24 
 
 
Discussion 
 
This was the first study performed to assess the use 
of insulin glargine in a real-life setting in patients with 
type 2 diabetes in Iran. The efficacy and safety of insulin 
glargine for patients with sub-optimally controlled 
T2DM while on OAD regimen were evaluated. We 
highlighted additional benefits of early treatment with 
insulin glargine in terms of efficacy and safety. Addition 
of insulin glargine to the OADs reduced HbA1c and 
fasting and postprandial blood glucose levels and 
improved lipid profile in patients with T2DM who were 
poorly controlled prior to the observation period. The 
results are in line with the data from previous 
international studies (22,24,28). No evidence of 
significant change in BMI or major/nocturnal 
hypoglycemic experiences were reported.  
This study addresses the trends to use of insulin 
earlier in the course of diabetes to prevent long-term 
complications of dysglycemia (31). The rationale for the 
early use of insulin includes increased insulin gene 
expression, improved insulin synthesis, rest to beta cells, 
and cell regeneration over time (17). Glargine is an 
insulin analog with no significant plasma peak after sub-
dermal injections (32). Its effect starts 1 hour after 
injection and lasts at least 24 hours in adults (33). The 
duration of action is shorter in children and use in 
pregnancy is not approved (34). It was first employed in 
Type 1 diabetes with the promising result and then in 
type 2 diabetes (24,35). Comparing NPH and glargine, 
ki-Jarvinen et al., reported improved glycemic control 
after additional use of either of the insulin types in 
patients on OAD and inadequate glycemic control (27). 
They showed that with similar insulin dosage and 
weight gain, subjects receiving combination therapy 
with glargine compared to NPH had less hypoglycemic 
events. It is known that same doses of glargine, and 
human insulin have equal effects on glucose disposal 
rate (36). These findings were confirmed later in large 
samples of diabetic patients with inadequate glycemic 
control on OADs (28). 
Glargine improves vasodilation and reduces long-term 
micro and macrovascular complications of diabetes (37) 
similar to human insulin (38) with comparably less 
hypoglycemic events (24,33,39-41). Nevertheless, the 
finding of this study concerning no significant clinical 
hypoglycemia is unique and may be biased with the 
impression and expression of the symptoms in Iranian 
patients as well as the target glycemic control. Of note in 
this study, insulin glargine dosing (with a mean daily dose 
of 20 IU after 24 weeks) was actually lower than in 
previous clinical studies where the mean daily dose 
ranged from 23 to 47 IU (22,26,27). A recent clinical trial 
in line with our findings demonstrated how glycemic 
control targets could be achieved with a low insulin dose 
in patients at an early stage of type 2 diabetes (28). 
The majorities of our patients were ≤60-year-old and 
were overweight. High blood glucose levels reported at 
the start of the study reflected the patients’ poor 
glycemic control on OADs and indicated the need for a 
change in their current treatment regimens. At the end of 
study approximately 65% of patients met the target 
HbA1c level of ≤7.5% after 24 weeks of treatment, 
indicating the role of insulin glargine in achieving 
glycemic targets in clinical practice. Further 
intensification of therapy, perhaps by adding one or 
more bolus short-acting insulin injections, would help 
improve glycemic control (27). We believe the 
improvements observed in the present study provide a 
foundation on which further therapies should be added.  
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The interpretation of our results should be concerned 
with the nature of the observational study. First, since a 
comparator group was not included, it is likely that some 
of the improvements observed may be related to a study 
effect rather than the pure therapeutic effect of insulin. 
Unfortunately, as this study was uncontrolled, it is not 
possible to precisely delineate the relationship between 
the study effect and the regimen used. Second, due to 
self-documentation of the outcomes and wide follow-up 
visit intervals, high proportion of lost participants and 
missing data occurred, and the adherence to the 
treatment habits was uncertain.  
Insulin glargine initiation in people with 
uncontrolled type 2 diabetes was associated with 
significant improvement in metabolic control.  Insulin 
glargine had a good safety profile and was well tolerated 
by the patients.  
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